Mazdutide
Tested in peopleGet notified when the evidence changes.
It has been tested in people, but it is not an approved medicine. The studies are usually small.
Compiled and reviewed by the PeptideSearch Editorial Team · Status checked 2026-08-04
Also called IBI362 / LY3305677
A weight-loss drug in human trials, developed mainly for the Chinese market.
Official status: Not nominated for 503A compounding · Checked 2026-08-04
Can a doctor prescribe this?
- Small pharmacy (503A)
- Never put forward to FDA
- Large outsourcing facility (503B)
- Never put forward to FDA
Investigational in the US. Not approved and not legal to compound.
503A is a pharmacy making a single prescription for one patient. 503B is a facility making batches. They are governed by separate lists. Where a category is shown, it is a position on the FDA's list of substances that have been put forward and are still being worked through — not the final list, which is set by rulemaking. Category 1 means the FDA does not plan to act against a pharmacy that makes it while the review runs.
Lab suppliers we list: 5
Doses used in research
Taken word for word from the studies and trials listed on this page. This is not a recommendation and not a dose for anyone to take.
- Study in peopleMazdutide versus Semaglutide for the treatment of type 2 diabetes and obesity: Rationale, design and baseline data of DREAMS-3 phase 3 trial.
Contemporary clinical trials · 2026
- Study in peopleTreatment With 9-mg Mazdutide for Weight Reduction in Chinese Adults With Obesity: The GLORY-2 Randomized Clinical Trial.
JAMA · 2026
- Study in peopleMazdutide 9 mg in Chinese adults with a body mass index ≥30 kg/m<sup>2</sup> but without diabetes: A phase 2 randomized controlled trial.
Med (New York, N.Y.) · 2026
- Study in peopleMazdutide versus placebo in Chinese adults with type 2 diabetes.
Nature · 2026
- Study in peopleMazdutide versus dulaglutide in Chinese adults with type 2 diabetes.
Nature · 2026
- Study in peopleEfficacy and safety of mazdutide in adults with obesity or overweight: a US-based, multicentre, phase 2, randomised, placebo-controlled clinical trial.
The lancet. Diabetes & endocrinology · 2026
- Study in peopleMazdutide reduces body weight in adults with overweight or obesity: A high-dose Phase 1 trial.
Diabetes, obesity & metabolism · 2025
- Study in peopleOnce-Weekly Mazdutide in Chinese Adults with Obesity or Overweight.
The New England journal of medicine · 2025
- Study in peopleEfficacy and Safety of Mazdutide in Chinese Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial.
Diabetes care · 2024
- Study in peopleA phase 2 randomised controlled trial of mazdutide in Chinese overweight adults or adults with obesity.
Nature communications · 2023
- Study in peopleA phase 1b randomised controlled trial of a glucagon-like peptide-1 and glucagon receptor dual agonist IBI362 (LY3305677) in Chinese patients with type 2 diabetes.
Nature communications · 2022
- Study in peopleSafety and efficacy of a GLP-1 and glucagon receptor dual agonist mazdutide (IBI362) 9 mg and 10 mg in Chinese adults with overweight or obesity: A randomised, placebo-controlled, multiple-ascending-dose phase 1b trial.
EClinicalMedicine · 2022
- Study in peopleIBI362 (LY3305677), a weekly-dose GLP-1 and glucagon receptor dual agonist, in Chinese adults with overweight or obesity: A randomised, placebo-controlled, multiple ascending dose phase 1b study.
EClinicalMedicine · 2021
- Data from people, not a trialAssessing the quality and reliability of health information on GLP-1 receptor agonists on TikTok and Bilibili: a cross-sectional analysis of the public health infodemic.
Therapeutic advances in endocrinology and metabolism · 2026
- Data from people, not a trialCase Report: Efficacy and safety of dose-escalated Mazdutide, a GLP-1/GCGR dual agonist, in an adolescent with obesity, type 2 diabetes, and hyperuricemia.
Frontiers in endocrinology · 2025
- Data from people, not a trialReview: Special Issue: <i>Real-world evidence on the use of GLP1 receptor agonists</i>: Emerging concepts in obesity management: focus on glucagon receptor agonist combinations.
Drugs in context · 2025
- Animal study, rats or miceMazdutide, a dual agonist targeting GLP-1R and GCGR, mitigates diabetes-associated cognitive dysfunction: mechanistic insights from multi-omics analysis.
EBioMedicine · 2025
- Lab dish studyMazdutide Ameliorates Non-Alcoholic Fatty Liver Disease by Modulating Endoplasmic Reticulum Stress
2026
- Lab dish studyMazdutide Ameliorates Metabolic Dysfunction-Associated Steatotic Liver Disease by Modulating Endoplasmic Reticulum Stress, Improving Lipid Metabolism and Alleviating Inflammation.
Pharmaceuticals (Basel, Switzerland) · 2026
- Lab test method, not a health studyDevelopment and validation of a multiplexed LC-HRMS method for nine GLP-1 receptor agonists and its pharmaceutical application.
Journal of chromatography. A · 2026
- No abstract available, not yet classifiedMazdutide and Orforglipron-New Evidence in Obesity and Diabetes.
JAMA · 2026
- No abstract available, not yet classifiedTreatment With 9-mg Mazdutide for Weight Reduction in Chinese Adults With Obesity: Research Summary.
JAMA · 2026
- Mazdutide: First Approval.
Drugs · 2025
- No abstract available, not yet classifiedOnce-Weekly Mazdutide in Obesity or Overweight. Reply.
The New England journal of medicine · 2025
- Review of earlier workPatent landscape and therapeutic evolution of mazdutide: a dual GLP-1/Glucagon receptor agonist for obesity and type 2 diabetes.
Expert opinion on therapeutic patents · 2026
- Review of earlier workComparative Efficacy and Safety of Glucagon Receptor Agonists on Metabolic Outcomes: A Network Meta-Analysis of Randomised Controlled Trials.
Endocrinology, diabetes & metabolism · 2026
- Review of earlier workEfficacy and Safety of the Dual Glucagon-Like Peptide-1 and Glucagon Receptor Agonist Mazdutide in Predominantly Chinese Adults With Obesity and/or Type 2 Diabetes: A Systematic Review and Meta-Analysis.
Diabetes, obesity & metabolism · 2026
- Review of earlier workCardiovascular Effects of Glucagon Receptor Signaling Alone and Combined With Glucagon-Like Peptide-1 Receptor Signaling in Multiagonists: A Narrative Review With a Translational Focus.
Journal of the American Heart Association · 2026
- Review of earlier workEfficacy and Safety of Mazdutide in Adults with Obesity or Overweight, With or Without Diabetes: A Bayesian Network Meta-Analysis
2026
- Review of earlier workEfficacy and Safety of Mazdutide in Managing Overweight and Obesity Among Non-Diabetic Adults: A Meta-Analysis of Randomised Controlled Trials.
Diabetes, obesity & metabolism · 2026
- Review of earlier workA Clinical Comprehensive Evaluation of Long-Acting GLP-1 Receptor Agonists in Type 2 Diabetes Management.
Diabetes, metabolic syndrome and obesity : targets and therapy · 2026
- Review of earlier workEfficacy and Safety of Mazdutide for Type 2 Diabetes: a GRADE assessed systematic review and meta-analysis of randomized controlled trials
2026
- Review of earlier workComparative efficacy and safety of glucagon-like peptide 1 based drugs for weight loss in adults with overweight or obesity without diabetes: network meta-analysis of randomised controlled trials.
BMJ medicine · 2026
- Review of earlier workIncretin-Based Dual and Triple Agonists in Overweight or Obese Individuals: A Systematic Review and Meta-Analysis.
Cardiology in review · 2026
- Review of earlier workBeyond weight loss: multisystem benefits of obesity medications.
The lancet. Diabetes & endocrinology · 2026
- Review of earlier workComparison of Mazdutide and Dulaglutide for Type 2 Diabetes: a GRADE assessed systematic review and meta-analysis of randomized controlled trials
2026
- Review of earlier workEfficacy of Mazdutide in Nondiabetic Adults with Overweight or Obesity: A Meta-Analysis
2025
- Review of earlier workEfficacy and safety of Mazdutide on weight loss among diabetic and non-diabetic patients: a systematic review and meta-analysis of randomized controlled trials.
Frontiers in endocrinology · 2024
- Review of earlier workSafety and efficacy of GLP-1 and glucagon receptor dual agonist for the treatment of type 2 diabetes and obesity: a systematic review and meta-analysis of randomized controlled trials.
Endocrine · 2024
Spot an error? corrections@peptidesearch.org